It’s been over three years since US regulators greenlit the nation’s first in-human test of Crispr’s disease-fighting potential, more than three years of waiting to find out if the much-hyped gene-editing technique could be safely used to beat back tough-to-treat cancers. Today, researchers from the University of Pennsylvania and Stanford finally revealed the first published report describing the trial.

Get in-depth coverage of current and future trends in technology, and how they are shaping business, entertainment, communications, science, politics, and society.

Advertisement